Vertex Pharmaceuticals stock heads toward November 2 earnings

Published on 10/06/2026 at 17:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharmaceuticals stock was trading at USD 502.91 on October 6, while its next earnings date is November 2, 2026. Q2 revenue rose 12.5 percent.

Wissenschaftler pipettiert Proben in modernem Biotech-Labor mit Automatisierungsgeräten — Vertex Pharma US92532F1003 zeigt einen Forscher im modernen Labor mit Pipette an sterilem Edelstahltisch, Illustration mit AI erstellt.

Vertex Pharmaceuticals stock was trading at USD 502.91 on Nasdaq on October 6, 2026 at 11:16 a.m. ET, down 0.12 percent from the prior close. The next confirmed earnings date is November 2, 2026, after the market closes, according to Stock Analysis.

November earnings set the checkpoint

The November report will test whether Vertex can maintain the growth rate shown in its latest reported quarter. In Q2 2026, revenue reached USD 3.33 billion, up 12.5 percent year over year, according to MarketBeat.

That result gives the upcoming release a clear operating benchmark: revenue growth must continue while Vertex expands beyond its cystic fibrosis franchise. The company is also developing therapies in kidney disease, acute pain and cell therapy, making pipeline execution central to the earnings narrative.

Kidney data add pipeline support

Vertex reported positive Phase 2b AMPLIFIED data for inaxaplin on September 22, 2026. In the cohort with APOL1-mediated kidney disease and modest proteinuria, urine albumin to creatinine ratio fell 42.7 percent at Week 13 from baseline, while the type 2 diabetes cohort recorded a 17.3 percent reduction, according to Finanznachrichten.

Vertex also completed enrollment in the Phase 2/3 AMPLITUDE trial, with interim analysis data planned for early 2027. The two cohort results point in different directions, so the November figures will matter for judging whether established products can fund the next growth phase.

Consensus target stays above Nasdaq price

MarketBeat shows a Moderate Buy consensus based on 23 analysts, with an average price target of USD 575.13, a high target of USD 665.00 and a low target of USD 442.00. The average target lies 14.36 percent above the Nasdaq price of USD 502.91 on October 6, 2026.

The same source lists a 52-week range of USD 400.73 to USD 560.25 and a market capitalization of USD 127.79 billion at the October 5 close. That valuation leaves the earnings release and pipeline milestones as the main measurable tests for the stock's premium.

Vertex Pharmaceuticals stock approaches earnings

Vertex Pharmaceuticals stock was last at USD 502.91 on Nasdaq on October 6, 2026 at 11:16 a.m. ET. The shares remain below the 52-week high of USD 560.25, while the November 2 earnings date provides the next scheduled company checkpoint.